FDA approves Fournier's estradiol transdermal patch Aug. 4 for the treatment of moderate to severe vasomotor symptoms associated with menopause; vulval and vaginal atrophy; and hypoestrogenism due to hypogonadism, castration, or primary ovarian failure. The drug will be available in five strengths: 0.025, 0.0375, 0.05, 0.075 and 0.1 mg/24 hours. Esclim will be marketed in the U.S. by Ares-Serono
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth